Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorJenna-Leigh Wilson

About this trial

Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient is 18 years of age or older

Patient is undergoing single stage ORIF of an ankle fracture

Patient is English-speaking

Disqualifiers

Patient is under 18 years of age

Patient's ankle fracture is treated with external fixation

Patient has a concomitant osseous or visceral injury

Patient has a history of opioid use disorder or a current diagnosis of opioid use disorder

Trial design

Design model

Parallel

Treatments tested in this trial

  • Buprenorphine Transdermal System

    Drug

    The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.

  • Placebo Patch

    Drug

    The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Buprenorphine Transdermal SystemExperimental treatment 1 intervention
Group B: Placebo PatchPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Morphine Milligram Equivalents of Full-agonist Opioid Consumed

After surgery, patients will record the total amount of opioid medication they consumed during the first post-operative week in their pain diary. In admitted patients, the electronic medical record will be reviewed to determine the morphine milligram equivalents of opioid consumed while admitted. Patients will also bring all their bottles and opioid prescriptions to their first post-operative clinic visit, at which point their total opioid consumption between surgery and their first post-operative clinic visit will be recorded by the researchers.

Time frame
Post-operative days 0-7. First post-operative clinic visit (approximately 3 weeks after surgery).

Secondary outcomes

1

Visual Analog Pain Scores

After surgery, visual analog pain scores with movement and at rest will be reported by the patient in a pain diary. In admitted patients, visual analog pain scores will be recorded by the bedside nurse. Visual analog pain scores are rated from 0-10. A score of 0 represents that the patient has no pain. A score of 10 represents excruciating pain.

Time frame
Postoperative days 1-8, 21, 90.
2

Morphine Milligram Equivalents of Full-Agonist Opioids Administered in Perioperative Setting

Review of the medication administration record will be performed to calculate the morphine milligram equivalents of opioid medication administered during ankle fracture surgery and in the post-operative recovery unit.

Time frame
Perioperative/Periprocedural
3

Adverse Effects Related to Opioid Medication

After surgery, patients will record whether they have symptoms of constipation, nausea, vomiting, drowsiness, or anything other symptoms potentially related to their opioid medication. The frequency and types of adverse effects will be recorded by the study researchers.

Time frame
Post-operative days 1-8, 21.
4

Hospital Readmissions due to Uncontrolled Post-operative Pain

The investigators will track the number of hospital readmissions due to uncontrolled post-operative pain.

Time frame
From patch application through post-operative day 21.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jenna-Leigh Wilson

Lead sponsor

Washington University School of Medicine

Sponsor institution

The Foundation for Barnes-Jewish Hospital

Collaborator

Washington University Institute of Clinical and Translational Sciences

Collaborator